多重用药对利伐沙班与华法林在非瓣膜性房颤中疗效与安全性的影响
在合并多重用药(≥5种慢性药物)的患者中,利伐沙班与卒中或系统性栓塞(SSE)风险降低34%(95%CI 12-50)及缺血性卒中风险降低40%(95%CI 16-57)相关,大出血发生率相似(HR 1.08,95%CI 0.92-1.28)。
要点
- 多重用药的非瓣膜性房颤患者中,利伐沙班较华法林降低SSE和缺血性卒中风险。
- 利伐沙班与华法林的大出血风险在多重用药患者中相似。
- 重度多重用药(≥10种慢性药物)亚组趋势一致但置信区间跨1.0。
核心结论
- 在多重用药的非瓣膜性房颤患者中,利伐沙班是华法林有效且安全的替代选择。
研究设计与样本
- 纳入口服抗凝药初治、有至少2个房颤诊断编码且无瓣膜性心脏病编码、有至少12个月连续保险覆盖、存在多重用药(≥5种独特慢性药物索赔)的成人患者。
- 利伐沙班组与华法林组按1:1倾向评分匹配,多重用药队列每组13981例,重度多重用药(≥10种慢性药物)队列每组1765例。
主要发现
- 在服用≥5种慢性药物的非瓣膜性房颤患者中,利伐沙班与SSE风险降低34%(95%CI 12-50)相关。
- 在服用≥5种慢性药物的非瓣膜性房颤患者中,利伐沙班与缺血性卒中风险降低40%(95%CI 16-57)相关。
- 在服用≥5种慢性药物的非瓣膜性房颤患者中,利伐沙班与华法林的大出血发生率相似(HR 1.08,95%CI 0.92-1.28)。
- 在重度多重用药(≥10种慢性药物)亚组中,SSE(HR 0.44)、缺血性卒中(HR 0.62)和大出血(HR 1.07)趋势相似,但95%CI均跨1.0。
临床怎么用
- 对于合并多重用药的非瓣膜性房颤患者,可考虑优先选用利伐沙班以降低卒中和系统性栓塞风险。
- 选用利伐沙班时无需因多重用药而担忧大出血风险显著增加。
- 重度多重用药患者的获益趋势一致但证据强度较弱,需个体化评估。
局限性
- 为回顾性索赔分析,可能存在未测量混杂。
- 重度多重用药亚组样本量较小,各结局95%CI均跨1.0。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: Patients with nonvalvular atrial fibrillation (NVAF) often have multiple comorbidities requiring concomitant medications in addition to their oral anticoagulant (OAC). The objective of this study was to evaluate the impact of polypharmacy on the effectiveness and safety of rivaroxaban versus warfarin in patients with NVAF managed in routine clinical practice. DESIGN: Retrospective claims analysis. DATA SOURCE: United States Truven MarketScan database (November 2012-March 2017). PATIENTS: Adults who were OAC naïve during the 12 months before the day of the first qualifying rivaroxaban or warfarin dispensing (index date); had at least two International Classification of Diseases, Ninth or Tenth Revision diagnosis codes for atrial fibrillation without codes suggesting valvular heart disease; had at least 12 months of continuous insurance coverage prior to the qualifying OAC dispensing; and were experiencing polypharmacy (concomitant prescription claims for five or more unique chronic medication claims) were included. Patients who had concomitant prescription claims for ≥ 10 unique chronic medication claims constituted the substantial polypharmacy cohort used in the secondary analysis. Patients receiving rivaroxaban were propensity-score matched in a 1:1 ratio to patients receiving warfarin (13,981 patients in each polypharmacy OAC group, and 1765 patients in each substantial polypharmacy OAC group). MEASUREMENTS AND MAIN RESULTS: Patients were followed until occurrence of an event (stroke or systemic embolism [SSE] combined [primary effectiveness outcome] or major bleeding [primary safety outcome]), OAC discontinuation or switch (30-day permissible gap), insurance disenrollment, or end of follow-up period. Rates of SSE, ischemic stroke, and major bleeding were compared by using Cox regression, reported as hazard ratios (HRs) and 95% confidence intervals (CIs). In patients with NVAF taking five or more chronic medications, rivaroxaban was associated with a 34% (95% CI 12-50) and 40% (95% CI 16-57) hazard reduction of SSE and ischemic stroke, respectively. Occurrence of major bleeding was similar between OAC cohorts (HR 1.08, 95% CI 0.92-1.28). A secondary analysis in patients with NVAF with substantial polypharmacy (taking ≥ 10 chronic medications) was also performed. Similar trends in SSE (HR 0.44), ischemic stroke alone (HR 0.62), and major bleeding (HR 1.07) were observed in patients with NVAF who had substantial polypharmacy, although 95% CIs crossed 1.0 for each outcome in this smaller study cohort. CONCLUSION: This real-world study suggests that in the setting of polypharmacy and NVAF, rivaroxaban is an effective and safe alternative to warfarin.
引用
- Martinez BK, Baker WL, Sood NA, et al. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation. Pharmacotherapy. 2019. PMID: 30597611. doi:10.1002/phar.2213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。